The market for using genetic scanning machines to analyze large swaths of DNA will grow by 20 percent to 30 percent annually, and is likely to reach $10 billion in the next few years, Life Technologies Corp. Chief Executive Officer Greg Lucier said.
Life Technologies Corp., a maker of DNA-sequencing equipment and laboratory materials, is in discussions with private-equity firms and health-care companies about a potential sale of the company, according to people familiar with the process.
Roche Holding AG Chairman Franz Humer may have put a lid for now on a year’s worth of speculation by telling a Swiss newspaper that a Roche deal to buy U.S. genetics company Illumina Inc. is off the table. Illumina shares fell the most in 15 months.
McKesson Corp., the largest U.S. pharmaceutical distributor, rose to its highest value ever after agreeing to buy Germany’s Celesio AG for about 3.9 billion euros ($5.4 billion) to boost its share of the growing global generic- drug market.
Life Technologies Corp. got takeover offers from a private-equity group including Blackstone Group LP, and from Thermo Fisher Scientific Inc., for as much as $11.8 billion, said people familiar with the matter.